The survival of patients with cystic fibrosis (CF) continues to improve. The discovery and
cloning of the CFTR gene more than 21 years ago led to the identification of the structure …

A significant increase in life expectancy in successive birth cohorts of people with cystic
fibrosis (CF) is a result of more effective treatment for the disease. It is also now widely …

Background Patients with chronic obstructive pulmonary disease (COPD) with an
eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal …

Rationale: Patients with cystic fibrosis periodically experience pulmonary exacerbations.
Previous studies have noted that some patients' lung function (FEV1) does not improve with …

Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene [1, 2]. This results in dysfunction of the apical membrane CFTR …

With the improving survival of patients with cystic fibrosis (CF), the clinical spectrum of this
complex multisystem disease continues to evolve. One of the most important clinical events …

With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic
defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the …

Since the late 1970s when the potential of the immunoreactive trypsinogen assay for early
identification of infants with cystic fibrosis was first recognised, the performance of newborn …

Infection Control Recommendations for Patients With Cystic Fibrosis: Microbiology,
Important Pathogens, and Infection Control Practices to Prevent Patient-to-Patient …

Pulmonary exacerbations have very important consequences in cystic fibrosis (CF), both in
terms of current morbidity as well as implications for long term morbidity and mortality. Even …